Abstract: Objective To explore the clinical significance and prognostic values of VEGFR-2，PDGFR-β and c-MET in patients with hepatocellular carcinoma（HCC）. Methods The expression of VEGFR-2，PDGFR-β and c-MET in 93 HCC patients was examined by immunohistochemistry（IHC）, and the correlation between clinical characteristics and progrosis was analyzed. Results The over-expression rates of VEGFR-2，PDGFR-β and c-MET in HCC were 86.0％，19.4％ and 80.6％，respectively. The expression of VEGFR-2 was related with sex，hepatitis B surface antigen（HBsAg） status，differentiation and hepatic cirrhosis（P＜0.05）. The expression of PDGFR-β was related with α-fetoprotein（AFP），number of tumor and hepatic cirrhosis（P＜0.05）. There was no significant relationship between the expression of c-MET and clinicopathological factors. Cox regression analysis showed that in 65 patients taking sorafenib，the progress free survival（PFS） was related to age（P=0.047），and the overall survival （OS） was related to HBsAg（P=0.037），AFP（P=0.015） and tumor size（P=0.003）. The expression of PDGFR-β was related with OS（P=0.046）. The expression of c-MET was related to PFS（P=0.01）. ConclusionThe expression level of VEGFR-2 is higher in HCC patients with hepatic cirrhosis. PDGFR-β is a biomarker for the poor prognosis in HCC patients. c-MET may be a prognostic factor to predict the therapeutic effect of HCC patients who have taken sorafenib.